It will be interesting how this works out for ITRM. We have seen it before where the FDA finds a reason besides actual trial efficacy or safety issues that cause a delay and price tanks. Then after finding out it is an issue not related to the trial performance and price rises quickly after details are know. I will be looking to gauge immediate reactions, look for lower entries as you are and find out the full story of what the FDA meant in their response letter. As far as is known, there is nothing wrong with the trial results data.
Volatility i the action when it comes to baby and emerging bios.
News 
Market Data 
Discover 
